{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:38:55Z","timestamp":1783615135235,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T00:00:00Z","timestamp":1339545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated a new chemoradiotherapy (CRT) regimen for locoregionally advanced nasopharyngeal carcinoma (NPC). A total of 240 patients were randomly assigned to three different CRT regimens: sequential CRT [1 cycle chemotherapy + Phase I radiotherapy (RT) + 1 cycle chemotherapy + Phase II RT + 2 cycles chemotherapy] with a cisplatin\u2013gemcitabine (GC) regimen (800 mg\/m<jats:sup>2<\/jats:sup> gemcitabine on Days 1 and 8 and 20 mg\/m<jats:sup>2<\/jats:sup> cisplatin on Days 1\u20135, every 4 weeks) (sGC\u2010RT); sequential chemoradiotherapy with a cisplatin\u2013fluorouracil (PF) regimen (20 mg\/m<jats:sup>2<\/jats:sup> DDP and 500 mg\/m<jats:sup>2<\/jats:sup> 5\u2010FU on Days 1\u20135, every 4 weeks) (sPF\u2010RT) and cisplatin\u2010based concurrent chemoradiotherapy plus adjuvant PF chemotherapy (Con\u2010RT + PF). The complete response rate was higher in the sGC + RT group than in the other two groups (98.75% <jats:italic>vs<\/jats:italic>. 92.50%, <jats:italic>p<\/jats:italic> &lt; 0.01). The 3\u2010year overall survival (OS), disease\u2010free survival (DFS) and distant metastasis\u2010free survival (DMFS) rates in the sGC\u2010RT group were significantly higher than those observed in the Con\u2010RT group (OS, 95.0% <jats:italic>vs<\/jats:italic>. 76.3%, <jats:italic>p<\/jats:italic> &lt; 0.001; DFS, 89.9% <jats:italic>vs<\/jats:italic>. 67.5%, <jats:italic>p<\/jats:italic> &lt; 0.001; DMFS, 92.5% <jats:italic>vs<\/jats:italic>. 76.0%, <jats:italic>p<\/jats:italic> = 0.004) and in the sPF + RT group (OS, 95.0% <jats:italic>vs<\/jats:italic>. 73.6%, <jats:italic>p<\/jats:italic> &lt; 0.001; DFS, 89.9% <jats:italic>vs<\/jats:italic>. 63.3%, <jats:italic>p<\/jats:italic> &lt; 0.001; DMFS, 92.5% <jats:italic>vs<\/jats:italic>. 74.7%, <jats:italic>p<\/jats:italic> = 0.002). There were no significant differences in 3\u2010year OS, DFS and MFS rates between the Con\u2010RT and the sPF\u2010RT groups. The GC\u2010RT group experienced more hematologic toxicity, constipation and rash; however, there were no differences in late RT toxicity between the groups. These results demonstrate that a sGC\u2010RT regimen is effective and well tolerated in patients with locoregionally advanced NPC.<\/jats:p>","DOI":"10.1002\/ijc.27638","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T12:14:36Z","timestamp":1337343276000},"page":"215-223","source":"Crossref","is-referenced-by-count":20,"title":["Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma"],"prefix":"10.1002","volume":"132","author":[{"given":"Mo\u2010Fa","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long\u2010Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Xin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang\u2010Yu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo\u2010Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua\u2010Man","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao\u2010Xian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2010Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,13]]},"reference":[{"key":"e_1_2_5_2_2","volume-title":"Cancer incidence in five continents, vol. 5. IARC Scientific Publications No. 88","author":"Muir CS","year":"1987"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10090289"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24201"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328344f527"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.7542"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq258"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20804"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf002"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf200"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20310"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.926"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-011-1669-9"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1350"},{"key":"e_1_2_5_16_2","first-page":"207","volume-title":"Nasopharyngeal carcinoma","author":"Tsao SY","year":"1991"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-C"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse P","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.04.004"},{"key":"e_1_2_5_21_2","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo","volume":"22","author":"Peters GJ","year":"1995","journal-title":"Semin Oncol"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(89)90319-2"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90316-6"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90005-M"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.16.790"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.06.016"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.02.012"},{"key":"e_1_2_5_28_2","first-page":"108","volume-title":"Radiation oncology, rationale, technique, results","author":"Milas L","year":"2003"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869509093999"},{"key":"e_1_2_5_30_2","unstructured":"A trial of adjuvant chemotherapy in nasopharyngeal carcinoma patients with residual Epstein\u2010Barr virus (EBV) DNA following radiotherapy. Available at:http:\/\/www.clinicaltrials.gov. Accessed on March 11 2010."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.4.1893-1902.2004"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605465"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0638-1"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.27638","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.27638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:18:50Z","timestamp":1697433530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.27638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/ijc.27638"],"URL":"https:\/\/doi.org\/10.1002\/ijc.27638","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,13]]}}}